Clinical Epigenetics Sections
Aging, development, imprinting and reproductive epigenetics: Section edited by Monika Puzianowska-Kuznicka, Akihiro Umezawa and Wolfgang Wagner
Developmental processes are governed by epigenetics and there is a growing evidence that this applies also to aging of the organism. Furthermore, genomic imprinting, the epigenetic phenomenon reducing expression of certain genes to either maternal or paternal alleles, as well as epigenetics in reproductive medicine are of increasing relevance. Likewise, epigenetic factors in prenatal and postnatal development as well as later in life significantly contribute to the rate and phenotype of aging. This section covers the full breadth of these interdisciplinary research areas. It aims for outstanding original contributions, which provide novel and sound insight into the underlying mechanisms of development and aging. Description of biomarkers or resource paper can also be considered if they significantly advance the field. Epigenetic raw data should be deposited in public data repositories. Studies on non-human model systems can also be considered if they provide insight into relevant epigenetic processes.
Allergy, immunology, pathogens and inflammation: Section edited by Georges Herbein, Rachel Miller and Kari Nadeau
This section publishes high-quality and innovative research generated from basic science, animal and translational clinical studies that focus on epigenetic regulation in the induction or control of allergic disease, asthma and other immune responses and on epigenetic mechanisms involved in infectious diseases and inflammation. Research on the application of epigenetic analyses to the prediction, diagnosis, and treatment of allergic disease, infectious diseases and inflammation are particularly welcomed. These may also include reports on the interface between environmental exposures and epigenetic changes important to allergy, asthma, immunology, inflammation and infectious diseases. Laboratory studies that report on potentially new epigenetic targets related to allergy, asthma, immunology, inflammation and infectious diseases will also be considered.
Cancer epigenetics and diagnostics: Section edited by Maria Berdasco, James Chim, Roderick Dashwood, Carmen Jerónimo, Eckart Meese, Arpad Patai and Ed Seto
The development of genome-wide techniques has rapidly improved the comprehensive knowledge of epigenetic alterations in cancer. Currently, a vast number of genes and their associated molecular pathways that show epigenetic differences between normal and tumoral cells have been identified, emphasizing the crucial role of epigenetic factors in cancer etiology and progression. This section publishes original epigenetic research focused on epigenetic profiling and its clinical value for future diagnosis, prognosis and prediction of response to therapies (pharmacoepigenetics).
Cardiovascular epigenetics: Section edited by Xiaoling Wang
The impact of epigenetics in cardiovascular disease is now emerging as an important player at different levels from etiology to therapeutics. This section publishes original epigenetic research and reviews in all cardiovascular medical specialties from both animal model and human studies. Research that links epigenetic regulation with cardiovascular risk factors, biomarkers and subclinical cardiovascular diseases will also be included in this section.
Endocrinology and metabolic disease: Section edited by Richard Saffery and Charlotte Ling
Non-communicable disorders of metabolic/endocrine origin are amongst the largest contributors to the burden of mortality and morbidity in the 21st century. Mounting evidence links epigenetic disruption throughout the life course in the etiology of such conditions, though a full understanding of their origin requires an in-depth examination of the interplay between genetic, epigenetic and environmental factors. Submissions to this section should increase our understanding of the role of epigenetic processes in the etiology of diseases of metabolic or endocrine origin in either animal model or human observational studies.
Epigenetic therapy and clinical trials: Section edited by Richard Momparler and Nick La Thangue
This section publishes research on the potential of epigenetic agents for the treatment of diseases. Manuscripts on both preclinical and early clinical studies are welcome. Preclinical studies should include the rationale for translation of the activity of epigenetic agents from the bench to the bedside. The clinical trials on epigenetic agents should include the background, rationale, clinical design and key endpoints.
Innovative epigenetic therapies: Section edited by Marianne Rots
Epigenome-wide association studies result in increasing lists of disease-associated epigenetic abnormalities. To exploit such mutations beyond their use as biomarkers, innovative epigenetic therapies (including but not limited to epigenetic editing) are expected to be further developed into the preclinical and clinical testing phase. This section publishes research and reviews on the development of epigenetic rewriting agents for the treatment of diseases, which do not belong to the conventional class of chemical epigenetic enzyme inhibitors.
Neurology and psychiatry: Section edited by Jonathan Mill
Neurological and psychiatric disease makes a huge contribution to the global burden of disease, but little is known about their underlying etiology. This section welcomes articles exploring the role of epigenetic processes across the spectrum of brain disorders. We are particularly interested in articles exploring the interplay between genetic, epigenetic and environmental factors, and the utility of molecular biomarkers for diagnostic and prognostic phenotyping. We would also welcome mechanistic studies exploring the functional pathways involved in mediating the effects of epigenetic variation in the central nervous system using disease-relevant tissue and model systems.
Nutritional and environmental epigenetics: Section edited by Carmen Marsit
Although epigenetic mechanisms are inherently stable through cell divisions, nutritional and environmental factors can shape the epigenetic landscape. This section aims to cover the breadth and depth of studies examining the impacts of nutritional factors and the environment, on epigenetic regulation. Nutrition may encompass the specific effects of nutrients as well as more holistic evaluation of dietary and eating patterns, while environmental factors can be broadly interpreted to include the chemical environment, psychosocial and demographic factors, the metabolic environment, pharmaceuticals and drugs of abuse. Articles in this section may use animal model or human population approaches to vigorously identify how nutritional and environmental factors impact the full range of epigenetic mechanisms and the implication of those changes or that variation on phenotypic outcomes.
All other subjects: Section edited by Lucia Altucci, James Davie, Eamonn Maher, Adele Murrell, Trygve O Tollefsbol and Bryan Turner
This section welcomes articles from any discipline of clinical epigenetics not covered by the other journal sections.